Abstract
Background: Cervical cancer affects women in the time that they are critical to economic and social stability.
Objective: The aim of this narrative review to assess the socio-economic consequences of cervical cancer.
Methods: In this review, Pubmed, Scopus, ISI web of science, Conferences databases and Iranian databases were searched. In order to search related articles, researchers used the following terms: “Uterine cervical neoplasms” OR ‘cervical cancer”; Costs and cost analysis; costs of illness, burden, socioeconomic. After the primary search, some records were obtained from 1960 to 2018. After studying titles, abstracts, and in some cases the full texts, 48 relevant articles were included in this research.
Results: Hospitalization costs were the highest direct costs. However, total social costs are higher than health and medical costs. There is a dramatic increase in direct costs with the increase in age and stage of the disease. The costs are less for people aged 75 and up and for stage 4 because of less invasive treatment received by older women and the limited choice of treatment in advanced stages. The costs for persons who were screened 6 months to 5 years before diagnosis were lower.
Conclusion: The burden of the disease is high. Early detection of cancer can save lives and reduce health care costs. Studies evaluating the costs associated with cervical cancer as well as virusrelated diseases in developing countries, calculating indirect costs and the impact of the disease on family members, relatives, and especially the spouse of the affected women are recommended.
Keywords: Uterine cervical neoplasms, economics, cost-effectiveness, review, burden, socioeconomic.
Graphical Abstract
[1]
Chan JL, Letourneau J, Salem W, et al. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery. Gynecol Oncol 2015; 139(1): 141-7.
[http://dx.doi.org/10.1016/j.ygyno.2015.07.105] [PMID: 26232519]
[http://dx.doi.org/10.1016/j.ygyno.2015.07.105] [PMID: 26232519]
[2]
Chhabra S, Bhavani M, Mahajan N, Bawaskar R. Cervical cancer in Indian rural women: trends over two decades. J Obstet Gynaecol 2010; 30(7): 725-8.
[http://dx.doi.org/10.3109/01443615.2010.501412] [PMID: 20925620]
[http://dx.doi.org/10.3109/01443615.2010.501412] [PMID: 20925620]
[3]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[4]
American Cancer Society. Global Cancer Facts and Figures. 2nd (Ed)Atlanta: American Cancer Society 2011; pp 1-52
[5]
Machii R, Saika K. Estimated disability-adjusted life year (DALY) in Asia in GLOBOCAN 2008. Jpn J Clin Oncol 2013; 43(8): 846-7.
[http://dx.doi.org/10.1093/jjco/hyt107] [PMID: 23894205]
[http://dx.doi.org/10.1093/jjco/hyt107] [PMID: 23894205]
[6]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787]
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787]
[7]
Hailu A, Mariam DH. Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study. BMC Cancer 2013; 13: 69.
[http://dx.doi.org/10.1186/1471-2407-13-69] [PMID: 23391288]
[http://dx.doi.org/10.1186/1471-2407-13-69] [PMID: 23391288]
[8]
Glajchen M. Psychosocial consequences of inadequate health insurance for patients with cancer. Cancer Pract 1994; 2(2): 115-20.
[PMID: 8055013]
[PMID: 8055013]
[9]
Mor V, Masterson-Allen S, Houts P, Siegel K. The changing need of patients with cancer at home. A longitudinal view. Cancer 1992; 69(3): 829-38.
[http://dx.doi.org/10.1002/1097-0142(19920201)69:3<829::AIDCNCR2820690335>3.0.CO;2-I] [PMID: 1730132]
[http://dx.doi.org/10.1002/1097-0142(19920201)69:3<829::AIDCNCR2820690335>3.0.CO;2-I] [PMID: 1730132]
[10]
Siegel K, Raveis VH, Houts P, Mor V. Caregiver burden and unmet patient needs. Cancer 1991; 68(5): 1131-40.
[http://dx.doi.org/10.1002/1097-0142(19910901)68:5<1131::AIDCNCR2820680541>3.0.CO;2-N] [PMID: 1913486]
[http://dx.doi.org/10.1002/1097-0142(19910901)68:5<1131::AIDCNCR2820680541>3.0.CO;2-N] [PMID: 1913486]
[11]
Houts PS, Lipton A, Harvey HA, et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 1984; 53(11): 2388-92.
[http://dx.doi.org/10.1002/1097-0142(19840601)53:11<2388::AIDCNCR2820531103>3.0.CO;2-A] [PMID: 6424925]
[http://dx.doi.org/10.1002/1097-0142(19840601)53:11<2388::AIDCNCR2820531103>3.0.CO;2-A] [PMID: 6424925]
[12]
Stommel M, Given CW, Given BA. The cost of cancer home care to families. Cancer 1993; 71(5): 1867-74.
[http://dx.doi.org/10.1002/1097-0142(19930301)71:5<1867::AIDCNCR2820710525>3.0.CO;2-7] [PMID: 8448751]
[http://dx.doi.org/10.1002/1097-0142(19930301)71:5<1867::AIDCNCR2820710525>3.0.CO;2-7] [PMID: 8448751]
[13]
Brooks J, Wilson K, Amir Z. Additional financial costs borne by cancer patients: a narrative review. Eur J Oncol Nurs 2011; 15(4): 302-10.
[http://dx.doi.org/10.1016/j.ejon.2010.10.005] [PMID: 21093369]
[http://dx.doi.org/10.1016/j.ejon.2010.10.005] [PMID: 21093369]
[14]
Berkman BJ, Sampson SE. Psychosocial effects of cancer economics on patients and their families. Cancer 1993; 72(9)(Suppl.): 2846-9.
[http://dx.doi.org/10.1002/1097-0142(19931101)72:9+<2846::AIDCNCR2820721515>3.0.CO;2-3] [PMID: 8402517]
[http://dx.doi.org/10.1002/1097-0142(19931101)72:9+<2846::AIDCNCR2820721515>3.0.CO;2-3] [PMID: 8402517]
[15]
Iżycki D, Woźniak K, Iżycka N. Consequences of gynecological cancer in patients and their partners from the sexual and psychological perspective. Przegl Menopauz 2016; 15(2): 112-6.
[http://dx.doi.org/10.5114/pm.2016.61194] [PMID: 27582686]
[http://dx.doi.org/10.5114/pm.2016.61194] [PMID: 27582686]
[16]
Butler L, Banfield V, Sveinson T, Allen K. Conceptualizing sexual health in cancer care. West J Nurs Res 1998; 20(6): 683-99.
[http://dx.doi.org/10.1177/019394599802000603] [PMID: 9842287]
[http://dx.doi.org/10.1177/019394599802000603] [PMID: 9842287]
[17]
Lowdermilk D, Germino BB. Helping women and their families cope with the impact of gynecologic cancer. J Obstet Gynecol Neonatal Nurs 2000; 29(6): 653-60.
[http://dx.doi.org/10.1111/j.1552-6909.2000.tb02079.x] [PMID: 11110336]
[http://dx.doi.org/10.1111/j.1552-6909.2000.tb02079.x] [PMID: 11110336]
[18]
Bradley CJ, Neumark D, Luo Z, Schenk M. Employment and cancer: findings from a longitudinal study of breast and prostate cancer survivors. Cancer Invest 2007; 25(1): 47-54.
[http://dx.doi.org/10.1080/07357900601130664] [PMID: 17364557]
[http://dx.doi.org/10.1080/07357900601130664] [PMID: 17364557]
[19]
Refaei M, Dehghan Nayeri N, Khakbazan Z, Yazdkhasti M, Shayan A. Exploring effective contextual factors for regular cervical cancer screening in Iranian women: A qualitative study. Asian Pac J Cancer Prev 2018; 19(2): 533-9.
[PMID: 29480997]
[PMID: 29480997]
[20]
Cheikh A, El Majjaoui S, Ismaili N, et al. Evaluation of the cost of cervical cancer at the National Institute of Oncology, Rabat. Pan Afr Med J 2016; 23: 209.
[http://dx.doi.org/10.11604/pamj.2016.23.209.7750] [PMID: 27347298]
[http://dx.doi.org/10.11604/pamj.2016.23.209.7750] [PMID: 27347298]
[21]
Novaes HMD, Itria A, Silva GAE, Sartori AMC, Rama CH, Soárez PC. Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil. Clinics (São Paulo) 2015; 70(4): 289-95.
[http://dx.doi.org/10.6061/clinics/2015(04)12] [PMID: 26017797]
[http://dx.doi.org/10.6061/clinics/2015(04)12] [PMID: 26017797]
[22]
Annemans L, Rémy V, Lamure E, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008; 11(1): 135-50.
[http://dx.doi.org/10.3111/13696990801961611] [PMID: 19450115]
[http://dx.doi.org/10.3111/13696990801961611] [PMID: 19450115]
[23]
Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in France. Vaccine 2011; 29(32): 5245-9.
[http://dx.doi.org/10.1016/j.vaccine.2011.05.018] [PMID: 21616117]
[http://dx.doi.org/10.1016/j.vaccine.2011.05.018] [PMID: 21616117]
[24]
Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012; 30(42): 6016-9.
[http://dx.doi.org/10.1016/j.vaccine.2012.07.056] [PMID: 22867718]
[http://dx.doi.org/10.1016/j.vaccine.2012.07.056] [PMID: 22867718]
[25]
Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus--related disease. Am J Obstet Gynecol 2004; 191(1): 114-20.
[http://dx.doi.org/10.1016/j.ajog.2004.01.042] [PMID: 15295351]
[http://dx.doi.org/10.1016/j.ajog.2004.01.042] [PMID: 15295351]
[26]
Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol 2003; 88(2): 96-103.
[http://dx.doi.org/10.1016/S0090-8258(02)00101-4] [PMID: 12586586]
[http://dx.doi.org/10.1016/S0090-8258(02)00101-4] [PMID: 12586586]
[27]
Insinga RP, Ye X, Singhal PK, Carides GW. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. Gynecol Oncol 2008; 111(2): 188-96.
[http://dx.doi.org/10.1016/j.ygyno.2008.07.032] [PMID: 18757080]
[http://dx.doi.org/10.1016/j.ygyno.2008.07.032] [PMID: 18757080]
[28]
Cromwell I, Ferreira Z, Smith L, et al. Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis. Curr Oncol 2016; 23(Suppl. 1): S14-22.
[http://dx.doi.org/10.3747/co.23.2914] [PMID: 26985142]
[http://dx.doi.org/10.3747/co.23.2914] [PMID: 26985142]
[29]
Pendrith C, Thind A, Zaric GS, Sarma S. Costs of cervical cancer treatment: population-based estimates from Ontario. Curr Oncol 2016; 23(2): e109-15.
[http://dx.doi.org/10.3747/co.23.2598] [PMID: 27122978]
[http://dx.doi.org/10.3747/co.23.2598] [PMID: 27122978]
[30]
van Ballegooijen M, Koopmanschap MA, Tjokrowardojo AJ, van Oortmarssen GJ. Care and costs for advanced cervical cancer. Eur J Cancer 1992; 28A(10): 1703-8.
[http://dx.doi.org/10.1016/0959-8049(92)90072-A] [PMID: 1389489]
[http://dx.doi.org/10.1016/0959-8049(92)90072-A] [PMID: 1389489]
[31]
Van Minh H, My NTT, Jit M. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC Health Serv Res 2017; 17(1): 353.
[http://dx.doi.org/10.1186/s12913-017-2297-x] [PMID: 28506297]
[http://dx.doi.org/10.1186/s12913-017-2297-x] [PMID: 28506297]
[32]
Berraho M, Najdi A, Mathoulin-Pelissier S, Salamon R, Nejjari C. Direct costs of cervical cancer management in Morocco. Asian Pac J Cancer Prev 2012; 13(7): 3159-63.
[http://dx.doi.org/10.7314/APJCP.2012.13.7.3159] [PMID: 22994727]
[http://dx.doi.org/10.7314/APJCP.2012.13.7.3159] [PMID: 22994727]
[33]
el M’Rini T, Arveux P, Gay C, et al. [Estimation of the treatment cost of cervical cancer]. Rev Epidemiol Sante Publique 1997; 45(6): 508-15.
[PMID: 9496581]
[PMID: 9496581]
[34]
Arveux P, Bénard S, Bouée S, et al. [Invasive cervical cancer treatment costs in France]. Bull Cancer 2007; 94(2): 219-24.
[PMID: 17337390]
[PMID: 17337390]
[35]
Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998; 34(12): 1889-93.
[http://dx.doi.org/10.1016/S0959-8049(98)00232-9] [PMID: 10023311]
[http://dx.doi.org/10.1016/S0959-8049(98)00232-9] [PMID: 10023311]
[36]
Ricciardi A, Largeron N, Giorgi Rossi P, et al. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori 2009; 95(2): 146-52.
[http://dx.doi.org/10.1177/030089160909500203] [PMID: 19579858]
[http://dx.doi.org/10.1177/030089160909500203] [PMID: 19579858]
[37]
Ferrandina G, Marcellusi A, Mennini FS, Petrillo M, Di Falco C, Scambia G. Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Gynecol Oncol 2010; 119(2): 243-9.
[http://dx.doi.org/10.1016/j.ygyno.2010.06.025] [PMID: 20650507]
[http://dx.doi.org/10.1016/j.ygyno.2010.06.025] [PMID: 20650507]
[38]
Tang CH, Pwu RF, Tsai IC, et al. Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system. Arch Gynecol Obstet 2010; 281(4): 683-95.
[http://dx.doi.org/10.1007/s00404-009-1218-6] [PMID: 19730873]
[http://dx.doi.org/10.1007/s00404-009-1218-6] [PMID: 19730873]
[39]
Dubas-Jakóbczyk K, Kocot E, Seweryn M, Koperny M. Production lost due to cervical cancer in Poland in 2012. Med Pr 2016; 67(3): 289-99.
[http://dx.doi.org/10.13075/mp.5893.00378] [PMID: 27364103]
[http://dx.doi.org/10.13075/mp.5893.00378] [PMID: 27364103]
[40]
Lipsy RJ. Assessing the short-term and long-term burden of illness in cervical cancer. Am J Manag Care 2008; 14(6)(Suppl. 1): S177-84.
[PMID: 18611085]
[PMID: 18611085]
[41]
Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004; 109(3): 418-24.
[http://dx.doi.org/10.1002/ijc.11719] [PMID: 14961581]
[http://dx.doi.org/10.1002/ijc.11719] [PMID: 14961581]
[42]
Hung MC, Liu MT, Cheng YM, Wang JD. Estimation of savings of life-years and cost from early detection of cervical cancer: a follow-up study using nationwide databases for the period 2002-2009. BMC Cancer 2014; 14: 505.
[http://dx.doi.org/10.1186/1471-2407-14-505] [PMID: 25011933]
[http://dx.doi.org/10.1186/1471-2407-14-505] [PMID: 25011933]
[43]
Arrossi S, Matos E, Zengarini N, Roth B, Sankaranayananan R, Parkin M. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. Gynecol Oncol 2007; 105(2): 335-40.
[http://dx.doi.org/10.1016/j.ygyno.2006.12.010] [PMID: 17258801]
[http://dx.doi.org/10.1016/j.ygyno.2006.12.010] [PMID: 17258801]
[44]
Ohara-Hirano Y, Kaku T, Hirakawa T, et al. Uterine cervical cancer: a holistic approach to mental health and it’s socio-psychological implications. Fukuoka Igaku Zasshi 2004; 95(8): 183-94.
[PMID: 15552960]
[PMID: 15552960]
[45]
Serin D, Dilhuydy JM, Romestaing P, et al. ‘Parcours de Femme 2001’: a French opinion survey on overall disease and everyday life management in 1870 women presenting with gynecological or breast cancer and their caregivers. Ann Oncol 2004; 15(7): 1056-64.
[http://dx.doi.org/10.1093/annonc/mdh265] [PMID: 15205199]
[http://dx.doi.org/10.1093/annonc/mdh265] [PMID: 15205199]
[46]
Ginindza TG, Sartorius B, Dlamini X, Östensson E. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. PLoS One 2017; 12(5) e0177762
[http://dx.doi.org/10.1371/journal.pone.0177762] [PMID: 28531205]
[http://dx.doi.org/10.1371/journal.pone.0177762] [PMID: 28531205]
[47]
Refaei M, Dehghan Nayeri N, Khakbazan Z, Pakgohar M. Cervical cancer screening in Iranian women: Healthcare practitioner perceptions and views. Asian Pac J Cancer Prev 2017; 18(2): 357-63.
[PMID: 28345331]
[PMID: 28345331]
[48]
Subramanian S, Trogdon J, Ekwueme DU, Gardner JG, Whitmire JT, Rao C. Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care. Womens Health Issues 2010; 20(6): 400-5.
[http://dx.doi.org/10.1016/j.whi.2010.07.002] [PMID: 21050999]
[http://dx.doi.org/10.1016/j.whi.2010.07.002] [PMID: 21050999]
[49]
Righolt CH, Pabla G, Mahmud SM. The direct medical costs of diseases associated with human papillomavirus infection in Manitoba, Canada. Appl Health Econ Health Policy 2018; 16(2): 195-205.
[http://dx.doi.org/10.1007/s40258-017-0367-1] [PMID: 29299769]
[http://dx.doi.org/10.1007/s40258-017-0367-1] [PMID: 29299769]
[50]
Oliva J, Lobo F, López-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ 2005; 6(4): 309-13.
[http://dx.doi.org/10.1007/s10198-005-0303-4] [PMID: 16133097]
[http://dx.doi.org/10.1007/s10198-005-0303-4] [PMID: 16133097]
[51]
Refaei M, Aghababaei S, Pourreza A, Masoumi SZ. Socioeconomic and reproductive health outcomes of female genital mutilation. Arch Iran Med 2016; 19(11): 805-11.
[PMID: 27845551]
[PMID: 27845551]
Article Metrics
3